Updated October 2026 with the FDA warning letters sent to exosome sellers in 2025 and 2026.

Exosome therapy is one of the fastest-growing offerings in aesthetic and orthopedic clinics: injected into scalps for hair loss, layered onto microneedled skin, injected into knees and shoulders, infused intravenously for vague promises of "anti-aging" or immune support. It is often positioned as the next generation beyond PRP or stem cells.

The underlying science is genuinely interesting. The commercial products being sold are a different question, and the U.S. Food and Drug Administration has been unusually direct about it.

Quick answers

Is exosome therapy FDA-approved? No. The FDA states that there are no FDA-approved exosome products, and that products claiming to treat a disease or condition are regulated as drugs and biological products — they need FDA approval, or at least an active investigational new drug application, before they can be marketed (FDA).

How safe are exosomes? No commercial exosome product has been through the FDA review that would establish its safety. In December 2019 the FDA issued a public safety notification after the Centers for Disease Control and Prevention brought it multiple reports of serious adverse events in patients in Nebraska treated with unapproved products marketed as containing exosomes (FDA).

What are the risks of exosome therapy? For illegally marketed regenerative medicine products — a group the FDA says includes exosomes — the agency lists blindness, tumor formation, neurological events, bacterial infections including life-threatening blood infections, reactions at the injection site, unwanted immune responses, and contamination with bacteria, viruses or mold during processing (FDA). Because no one outside the seller verifies what is in the vial, whether it is sterile, or whether the dose is consistent, the risk can differ from one batch to the next.

Is there recent FDA news on exosomes? Yes. The FDA has kept sending warning letters to companies selling exosome products, most recently in May and August 2026 — they are listed further down this guide.

The rest of this guide explains each of these in detail.

What exosomes actually are

Exosomes are tiny membrane-bound sacs — roughly 30 to 150 nanometers across — that cells release into their surroundings. They are one type of what researchers call extracellular vesicles. They carry proteins, lipids, and genetic material such as messenger RNA and microRNA, and they appear to be a way cells signal to one another.

That cargo is why researchers are interested. If a stem cell's benefit comes largely from the signals it sends rather than the cell itself, then in principle you could deliver the signals without the cell. Exosomes are also being studied as drug-delivery vehicles and as diagnostic biomarkers in cancer. A widely cited 2020 review in Science lays out the biology and the range of proposed biomedical applications (Kalluri and LeBleu, Science, 2020).

None of that is the same as evidence that a vial sold to a clinic does what the brochure says.

Is exosome therapy FDA-approved? No

This is the single most important fact in this guide, and it is not a technicality.

The FDA states plainly that there are no FDA-approved exosome products, and that products claiming to contain exosomes for the treatment of disease or conditions are regulated as drugs and biological products — meaning they require an approved biologics license application, or at minimum an active investigational new drug application, before they can be marketed (FDA Public Safety Notification on Exosome Products).

Sellers sometimes argue that exosome products fall under the lighter-touch pathway for human cells, tissues, and cellular and tissue-based products — the "361 HCT/P" route in 21 CFR Part 1271, which allows certain minimally manipulated tissues used for the same basic function they served in the donor to be distributed without premarket approval. The FDA's position is that exosome products generally do not qualify. They are processed well beyond minimal manipulation, and injecting umbilical-cord- or placenta-derived vesicles into a scalp or a joint is not "homologous use."

What "not FDA-approved" does and doesn't mean

It does not mean the FDA has reviewed exosome therapy and rejected it. No agency has concluded it doesn't work.

It does mean that no manufacturer has completed the trials required to demonstrate that a specific product is safe and effective for a specific use, and that no one outside the company has verified what is actually in the vial, whether it is sterile, or whether the dose is consistent from batch to batch. Approval is the process that produces those answers. Without it, you are relying on the seller's word.

It also means the usual consumer backstops are missing. There is no approved label, no required adverse-event reporting to a public database in the way approved drugs have, and no recall infrastructure tied to a marketing authorization.

How safe are exosomes? The FDA safety notification

On December 6, 2019, the FDA issued a public safety notification after the Centers for Disease Control and Prevention brought it multiple reports of serious adverse events in patients in Nebraska who had been treated with unapproved products marketed as containing exosomes (FDA). The notice does not describe the individual cases.

That is the core of the concern. These are biologic products derived from human tissue, often prepared in facilities that have not been inspected against the standards required for injectable biologics. A contaminated batch injected into a joint or infused intravenously is not a minor complication.

What are the risks of exosome therapy?

The FDA groups exosomes with other unapproved regenerative medicine products and says it has received reports of blindness, tumor formation, infections and more from their use. Its list of safety concerns for any illegally marketed regenerative product includes (FDA):

  • Blindness
  • Tumor formation
  • Neurological events
  • Bacterial infections, including life-threatening blood infections
  • Reactions at the site of collection and administration
  • An unwanted inflammatory or immune response
  • Cross-contamination with bacteria, viruses or mold during processing, and products not tested for infectious diseases such as hepatitis and HIV

Not every one of these has been reported for exosomes specifically — the FDA's list covers the whole category of unapproved regenerative products. The point is that without approval, nobody independent has checked a given product against any of them.

Latest FDA actions on exosome products (2025–2026)

The FDA has kept sending warning letters to companies marketing exosome products. Each letter below is public on the FDA's website, and each one treats the product as an unapproved new drug and an unlicensed biological product:

  • August 14, 2026 — R3 Medical Companies, Scottsdale, AZ. The letter names exosome products sold as ReBellaXO, ReBellaXOL, BelloXO and BelloXOL, and also cites manufacturing (CGMP) violations, including a failure to follow procedures designed to prevent microbiological contamination. The FDA added that the manufacturing process did not appear to isolate exosomes at all (FDA warning letter).
  • May 26, 2026 — Blue Horizon International, Hackensack, NJ. An "Exosome Therapy" derived from umbilical-cord (Wharton's jelly) stem cells (FDA warning letter).
  • September 24, 2025 — New Life Medical Services. An exosome-based product (FDA warning letter).
  • August 15, 2025 — Platinum Biologics, Orlando, FL. Exosome products sold as NanoEx and Nano Xsomes (FDA warning letter).
  • May 5, 2025 — Supreme Rejuvenation. Exosome products, with the FDA pointing the company to its 2019 exosome safety notification (FDA warning letter).

A warning letter is not a finding that a product hurt anyone. It is the FDA telling a company, in public, that it is selling something that legally needs an approval it does not have.

The agency's broader position on unapproved regenerative products is summarized in its patient-facing guidance (FDA: important patient and consumer information about regenerative medicine therapies).

Enforcement has been uneven, and the practical result is that products remain widely available in clinics. Availability is not authorization.

Does exosome therapy work? What the human evidence shows

Thin.

The preclinical literature — cell culture and animal models — is substantial and in places encouraging, particularly for wound healing and cartilage. The human clinical literature is mostly small case series, uncontrolled reports, and industry-adjacent studies, with heterogeneous products that cannot be compared to one another. Two vials labeled "exosomes" from different suppliers may differ enormously in vesicle count, purity, cell source, and what else is in the preparation. There is no standardized potency measure.

For the most commonly marketed cosmetic uses — hair density, skin texture, post-procedure recovery — there are published reports suggesting improvement, but almost none with the randomization, blinding, and control arms needed to separate the product from the procedure. Microneedling alone improves skin. Injecting fluid into a scalp alongside other treatments confounds attribution.

If you want to see where legitimate development stands, you can search registered trials at ClinicalTrials.gov. A serious program will have a registered study with a protocol; a clinic offering the treatment for cash will usually not.

This is a meaningfully weaker evidence base than PRP, which — while itself mixed and inconsistently standardized — has multiple randomized controlled trials and systematic reviews behind it in several indications.

How much does exosome therapy cost?

Exosome treatments are not covered by insurance, and most clinics do not publish a price: across every clinic in this directory, only a handful show one on their own website (PRP Atlas in numbers). What you are quoted will depend on the region, the product volume, the number of sessions and whether the exosomes are combined with another procedure, so ask for a written quote that names the product before you commit.

Whatever the figure, you are paying out of pocket for a product with less human evidence behind it than established alternatives.

Questions worth asking before you consent

  • What is the source material, and who manufactures it? Ask for the name.
  • Is this product the subject of an active investigational new drug application with the FDA? If the answer is vague, treat that as a no.
  • How is sterility tested, and by whom?
  • What is the specific evidence for this use — in humans, with a control group?
  • What happens if I have an adverse reaction, and who reports it?
  • Would PRP or an established treatment be a reasonable option here, and why is this better?

A clinician who cannot answer the first three is not in a position to obtain informed consent for an injectable biologic.

The honest bottom line

Exosomes may well become an important therapeutic class. The biology is plausible and the research is real. But "promising research field" and "product you should pay several thousand dollars for today" are different claims, and the gap between them is exactly what FDA approval exists to close.

Right now, no exosome product has crossed it, and the FDA has warned patients about the ones being sold. Some people will decide the potential upside is worth it anyway. That is a legitimate personal choice — but it should be made knowing that you are the trial, and no one is collecting the data.

This guide is information, not medical advice. Discuss any treatment decision with a qualified clinician who knows your history.